[Translation] A single-center, randomized, open-label, single-dose, two-formulation, two-sequence, two-period, double-crossover human bioequivalence study of vonoprazan fumarate tablets (20 mg) in healthy Chinese subjects under fasting and fed dosing conditions
主要研究目的:按有关生物等效性试验的规定,选择Takeda Pharmaceutical Company Limited为持证商的富马酸伏诺拉生片(商品名:Vocinti(沃克),规格:20mg)为参比制剂,对受试制剂富马酸伏诺拉生片(规格:20mg)(生产企业:四川科伦药业股份有限公司,上市许可持有人:陕西天宇制药有限公司)进行空腹和餐后条件下给药的人体生物等效性试验,比较受试制剂中药物在健康受试者体内的吸收速度和吸收程度与参比制剂的差异是否在可接受的范围内,评价两种制剂在空腹和餐后给药条件下的生物等效性。
次要研究目的:观察中国健康受试者口服受试制剂富马酸伏诺拉生片(规格:20mg)和参比制剂富马酸伏诺拉生片(商品名:Vocinti(沃克),规格:20mg)的安全性。
[Translation] Main purpose of the study: According to the relevant provisions of bioequivalence tests, Takeda Pharmaceutical Company Limited was selected as the reference preparation for the vonoprazan fumarate tablets (trade name: Vocinti (Walker), specification: 20mg) as the licensee, and the test preparation vonoprazan fumarate tablets (specification: 20mg) (manufacturer: Sichuan Kelun Pharmaceutical Co., Ltd., marketing authorization holder: Shaanxi Tianyu Pharmaceutical Co., Ltd.) was subjected to human bioequivalence tests under fasting and postprandial conditions, to compare whether the absorption rate and degree of the drug in the test preparation in healthy subjects are within the acceptable range with the reference preparation, and to evaluate the bioequivalence of the two preparations under fasting and postprandial conditions.
Secondary purpose of the study: To observe the safety of oral administration of the test preparation vonoprazan fumarate tablets (specification: 20mg) and the reference preparation vonoprazan fumarate tablets (trade name: Vocinti (Walker), specification: 20mg) to healthy Chinese subjects.